KUMC Confidentiality of Sponsor Information
To set forth the obligations to keep confidential certain information pertaining to sponsored research.
The University of Kansas Medical Center (KUMC), the KU Medical Center Research Institute, Inc. (KUMCRI), and each of their affiliated entities engaged in the conduct or administration of research supported by KUMC and KUMCRI.
All researchers have an obligation to keep sponsor proprietary or sensitive information confidential, in accordance with state and federal law, and KUMC and sponsor requirements.
If the research is a clinical trial, do not share confidential information about the trial in writing unless the exact wording has been approved in writing by: 1. The sponsoring agency, and 2. the KUMC Institutional Review Board (IRB), and 3. the KUMCRI for specific stipulations regarding publication, refer to the original, signed contract.
When KUMCRI enters into a research contract with a faculty member and a funding source, there is almost always a confidentiality agreement section that binds all parties to non-disclosure of certain information without written approval of the other parties. In clinical trial research, this is always the case. The investigator, and anyone involved in the trial who received information regarding the protocol, must keep all information strictly confidential. Information which is usually confidential includes the name of the company, the drug information, the protocol number, the dosage, etc. Most companies will not allow the title of the trial to be posted or advertised on lists. Listing of trials for the purpose of recruitment of patients, even when only done in the corridors or offices of the clinics, does not maintain confidentiality. Some staff have chosen to list the title of the trials on their CV as evidence of their research experience. The aforementioned examples must have written approvals. An example of the type of general information that can be shared is, “A multi-center, double-blind study for a long-acting beta agonist for subjects with asthma”. Care must be taken when sharing information verbally with others on the staff or in situations where staff can be overheard by patients, visitors, or other unauthorized persons. Companies are very serious about confidential information. Protection of human subjects’ information is very seriously monitored by the HSC. Breach of contract by disclosure of confidential information is a very serious offense for the KUMCRI and KUMC.
Separate policies and procedures apply to the confidentiality of individually identifiable research data. Use and Disclosure of Protected Health information for research purposes must comply with the requirements of the Health Insurance Portability and Accountability Act and HIPAA’s Privacy and Security Rule.
Associate Vice Chancellor for Research Administration: 913-588-5436
Director of Sponsored Programs Administration: 913-588-1261
05/06/2016: Removed Date Last Reviewed
04/18/2016: Uploaded into Policy Library
11/15/2015: Updated contacts
11/15/2007: Effective Date
9/26/2007: RAC Approved